| Anti-tumor potential of IMP dehydrogenase inhibitors: a century-long story R Naffouje, P Grover, H Yu, A Sendilnathan, K Wolfe, N Majd, EP Smith, ... Cancers 11 (9), 1346, 2019 | 104 | 2019 |
| Metabolic tumor volume on interim PET is a better predictor of outcome in diffuse large B-cell lymphoma than semiquantitative methods E Malek, A Sendilnathan, M Yellu, A Petersen, M Fernandez-Ulloa, ... Blood Cancer Journal 5 (7), e326-e326, 2015 | 39 | 2015 |
| Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States R Agarwal, A Sendilnathan, NI Siddiqi, S Gulati, A Ghose, C Xie, ... Journal of gastrointestinal oncology 7 (6), 996, 2016 | 25 | 2016 |
| Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma ET Lam, MKK Wong, N Agarwal, BG Redman, T Logan, D Gao, TW Flaig, ... Journal of Immunotherapy 37 (7), 360-365, 2014 | 25 | 2014 |
| Oncolytic virotherapy for head and neck cancer: current research and future developments A Malhotra, A Sendilnathan, MO Old, TM Wise-Draper Oncolytic Virotherapy, 83-93, 2015 | 16 | 2015 |
| Decreased plasma DEK oncogene levels correlate with P16-negative disease and advanced tumor stage in a case–control study of patients with head and neck squamous cell carcinoma T Wise-Draper, A Sendilnathan, S Palackdharry, N Pease, J Qualtieri, ... Translational Oncology 11 (1), 168-174, 2018 | 9 | 2018 |
| Lymphopenia as a predictor of survival in chemoradiation (CRT)-treated stage III non-small cell lung cancer (NSCLC). M Yellu, F Fakhrejahani, J Ying, M Mierzwa, E Malek, S Haque, ... Journal of Clinical Oncology 33 (15_suppl), e18513-e18513, 2015 | 9 | 2015 |
| PS06. 06 Immune Checkpoint Markers in Lung Large Cell Neuroendocrine Carcinomas (L-LCNEC): Topic: Medical Oncology NA Karim, A Sendilnathan, I Eldessouki, M Orr-Asman, C Xie, J Wang, ... Journal of Thoracic Oncology 12 (11), S1583-S1584, 2017 | 8 | 2017 |
| Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2 DM Gill, DD Stenehjem, K Parikh, J Merriman, A Sendilnathan, ... ecancermedicalscience 10, 2016 | 7 | 2016 |
| Safety and efficacy of sequencing high-dose interleukin 2 (IL2) after tyrosine kinase inhibitor (TKI) therapy for metastatic renal cell carcinoma. ET Lam, MKK Wong, N Agarwal, BG Redman, T Logan, TW Flaig, ... Journal of Clinical Oncology 29 (15_suppl), e15079-e15079, 2011 | 2 | 2011 |
| Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with high-dose … J Merriman, K Parikh, SK Tantravahi, AM Straubhar, AM Agarwal, ... Journal of Clinical Oncology 32 (15_suppl), 4577-4577, 2014 | 1 | 2014 |
| How anti-c in a D–patient prompted lifesaving work between a transfusion service and a blood center reference laboratory G Patch, J Maurer, A Sendilnathan, C Leak, E Nartowicz, V Kavitsky, ... Immunohematology 40 (2), 73-77, 2024 | | 2024 |
| Acknowledgment to the Reviewers of International Journal of Molecular Sciences in 2022 IE Office International Journal of Molecular Sciences 24 (3), 2105, 2023 | | 2023 |
| JCHIMP 12th Anniversary Issue G Junker, R Alweis, R Ferguson Journal of Community Hospital Internal Medicine Perspectives 13 (4), 97, 2023 | | 2023 |
| Acknowledgment to the Reviewers of International Journal of Molecular Sciences in 2022 A Doren, A Rahdar, AG Soboleva, AMM Jalil, A Ganesan, A Elangovan, ... Int. J. Mol. Sci 24, 2105, 2023 | | 2023 |
| Investigation of IMPDH2 overexpression in renal cell carcinoma (RCC) & its association with oncologic outcomes. A Sendilnathan, RK Velagapudi, A Marinos Velarde, R Jandarov, Z Zhu, ... Journal of Clinical Oncology 37 (7_suppl), 594-594, 2019 | | 2019 |
| Plasma concentrations of the DEK oncogene correlate with pathological variables in a case-control study of patients with HNSCC T Wise-Draper, A Sendilnathan, S Palackdharry, N Pease, J Qualtieri, ... Clinical Cancer Research 23 (23_Supplement), 50-50, 2017 | | 2017 |
| Association of quality of life (QOL) with oncologic and functional outcomes in head and neck cancer (HNC) patients (pts). A Sendilnathan, R Agarwal, A Deeb, R Bach, C Xie, F Kaval, C Robinson, ... Journal of Clinical Oncology 34 (15_suppl), e18139-e18139, 2016 | | 2016 |
| Advanced biliary tract cancer: Experience with ABC-02 regimen in a tertiary care center in the United States. R Agarwal, NI Siddiqi, S Gulati, A Sendilnathan, C Xie, OO Olowokure Journal of Clinical Oncology 34 (15_suppl), e15624-e15624, 2016 | | 2016 |
| The DEK Oncogene Can Be Detected in the Plasma of Head and Neck Cancer Patients and May Be Correlated With Tumor Immune Response and Prognosis T Wise-Draper, N hashemi Sadraei, A Sendilnathan, N Pease, J Qualtieri, ... International Journal of Radiation Oncology, Biology, Physics 94 (4), 940, 2016 | | 2016 |
